EZH2 and breast cancer: As well, on the side of TAMs that are educated by EZH2 inhibitor-treated BC cells, the increased IL-10 secretion stimulates EGFR-SRC signaling to enhance cell motility and the increased VEGF secretion accelerates vasculature development, which contribute to tumor metastasis all together.